medcelerator · clinician one-pager

First FDA-Approved Treatment for Ataxia in Ataxia-Telangiectasia

Aqneursa (levacetylleucine) — oral suspension for ataxia in ataxia-telangiectasia

FDA Approved · United States · September 21, 2026

Condition: Ataxia-Telangiectasia

Who this is for

This is for people living with ataxia-telangiectasia — and the caregivers who help them — who weigh at least 15 kg and may be candidates for labelled US Aqneursa oral suspension for ataxia. It explains the first FDA-approved A-T ataxia therapy (18 Sep 2026), the IB1001-303 fSARA results, weight-based packet dosing, embryo-fetal and fall/laceration honesty, AQNEURSA Cares navigation, and why authorised is not funded — without treating Aqneursa as a cure for immunodeficiency or cancer risk, treating completed research as walk-in enrolment, or importing US packets. Authorized is not funded.

Next clinical step

This is FDA authorised, not Health Canada authorised. Ask the clinician about US care, a trial, or a Special Access Programme path in United States.

Access doors

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
FDA Expanded Access (Patient Affairs)
US Food and Drug Administration path for a licensed clinician to request an investigational medical product for a patient with a serious or immediately life-threatening condition when no comparable approved therapy is available. This is a request path, not a labelled indication. Authorized is not funded.
https://www.fda.gov/news-events/public-health-focus/expanded-access

Not medical advice. Authorized is not funded. Full piece: https://medcelerator.com/articles/aqneursa-levacetylleucine-ataxia-telangiectasia